clinical trial · NCT00368537
Study Comparing the Safety and Efficacy of Tigecycline With Ampicillin-Sulbactam or Amoxicillin-Clavulanate to Treat Skin Infections
Wyeth is now a wholly owned subsidiary of Pfizer·phase4·completed·n = 550
Skin Diseases, BacterialTigecyclineampicillin-sulbactam
brief summary
The purpose of this study is to compare the safety and efficacy of the antibiotic tigecycline with other antibiotics, ampicillin-sulbactam, and amoxicillin-clavulanate in the treatment of a complicated skin and/or skin structure infection (cSSSI).
started
Sep 1, 2006
primary completion
Sep 1, 2008
completion
Sep 1, 2008
last updated
Sep 15, 2026
official title
A Multicenter, Randomized, Open-Label Comparison of the Safety And Efficacy of Tigecycline With That of Ampicillin-Sulbactam or Amoxicillin-Clavulanate to Treat Complicated Skin And Skin Structure Infections
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol